This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEDAF0IH_M.jpg
J&J announced earnings per share of $2.30 on revenue of $20.69 billion, compared with expectations of EPS of $1.99 on revenue of $19.86 billion.
The drug and consumer products company also boosted its dividend by 6.3% from $0.95 per share to $1.01 per share, offsetting a downbeat full-year outlook. .
“Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate,” said Alex Gorsky, Chairman and Chief Executive Officer. “We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.”
J&J shares rose over 4% premarket on the back of these figures.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
